Background
==========

Tobacco use is the single most preventable cause of death \[[@B1]\], associated with more than five million deaths annually worldwide \[[@B2]\]. By 2030, tobacco related mortality is likely to rise to more than 8 million people \[[@B2]\]. Up to half of the world's more than one billion smokers will die prematurely of a tobacco-related disease \[[@B2]\]. Therefore, reducing the burden of disease from smoking is obviously of paramount importance in the field of public health.

In Israel, 2014 mid-year population 8,227,200 \[[@B3]\], smoking prevalence among Jews has declined over the period 1980-1997-2010 from 45.0%-32.4%-23.9% among males and from 30.9%-25.0%-16.0% among females \[[@B4]\]. Amongst the non-Jewish population the decline has been far less over the period 1997--2010 from 46.9% to 43.4% among males, with a slight rise from 5.5% to 6.5% among females.

In Israel, the first estimate of smoking attributable mortality (SAM) was made for the 2001 National Gillon Commission to decrease damage from smoking \[[@B5]\]. This estimated 9,527 deaths from active smoking in 1999 and a further 1,385 deaths from passive or enforced smoking by foetuses, children, spouses and workmates. These estimates assumed a nine year lag period for each diagnosis, ignored elevated risks in ex-smokers and did not use age-specific risk categories.

An improved SAM estimate of 8,664 deaths attributable to active smoking in 2003 was published \[[@B6]\], based on the expansion of categories in the US Centres for Disease Control \[[@B7]\] on-line user-friendly computational program, called SAMMEC (Smoking Attributable Mortality, Morbidity, and Economic Costs). This estimate was based on

a\) SAMMECs diagnosis list \[[@B7]\] which in turn was based on the 2004 US Surgeon General's Report \[[@B8]\].

b\) The enormous body of US and international literature on health risks due to tobacco use, which includes major studies \[[@B9]\] and compendiums of studies \[[@B10]\]. This was in order to correct for omitted diagnoses in the SAMMEC list such as diabetes which had subsequently been proven to be smoking-related \[[@B11]\].

More importantly, the estimates corrected for the fact that the standard SAMMEC approach did not consider the latency period that occurs between exposure to the risk factor (tobacco) and tobacco-induced mortality. The estimates also expanded age categories to include persons under 35 years old (who were excluded from the SAMMEC estimates).

In 2007, SAM from active smoking was estimated to be 8,932 deaths \[[@B5]\] using similar methodology to the 2003 estimates \[[@B6]\].

At the request of the ministry's public health department, we were asked to prepare estimates of mortality and monetary costs attributable to smoking in 2014 in Israel for inclusion into the minister's report to parliament on smoking in Israel, which was published in May 2014 \[[@B4]\].

Methods
=======

Historical prevalence data on smokers was based on data bases of the Ministry of Health's health promotion department, National Health Surveys carried out by the Central Bureau of Statistics (1996--7 and 1999), bi-annual national telephone surveys (starting in 1994, the latest one for 2013 being based on 6,014 respondents) and National Health Surveys carried out by the Israeli Center for Disease Control (2003--4 and 2007--2010) \[[@B4]\]. The basic methodology, including updated prevalence surveys for current and ex-smokers by age and gender \[[@B4]\], mortality rates and relative risk (RR) estimates is described in detail an earlier paper \[[@B6]\]. Smoking prevalence data for 2014 was estimated by applying the relative decrease in gender and religion specific prevalence rates from 2012 to 2013 to the period 2013 to 2014. These included not only persons who reported smoking cigarettes but also those who reported using other tobacco products (like the hookah).

All calculations were based on an estimated mid-year population in 2014 of 8,227,200 persons \[[@B3]\]. Cost were at 2014 price levels using an average exchange rate for the first half of 2014 of 3.481 NIS to the US dollar \[[@B14]\].

The surgeon general's report of 2014 \[[@B13]\] was used to provide the widely acceptable rubric of disease categories providing up to date estimates of RR. Since it contained many highly aggregated categories (other cancers, other heart diseases, other vascular diseases), we dis-aggregated the categories using values in the SAMMEC categorization \[[@B7]\]. Meta-analyses of studies were used to provide RRs for peptic ulcers \[[@B14]-[@B16]\], Crohn's disease \[[@B17]-[@B21]\] and ulcerative colitis in former smokers \[[@B17]-[@B19],[@B21]-[@B23]\]. To complete the list of diagnoses (Table [1](#T1){ref-type="table"}), we added the specific (protective effects) of Parkinson's disease \[[@B24]-[@B26]\], endometrial cancer \[[@B27]-[@B29]\] and ulcerative colitis in current smokers \[[@B17]-[@B23]\].

###### 

Relative risk (RR) of SAM by smoking status, diagnosis and gender

  **Refs.**                                                                                        **Males RR current**          **Females RR current**    
  -------------------------- --------------------------------------------------------------------- ---------------------- ------ ------------------------ ------
                             **Cancers:**                                                                                                                  
  \[[@B7]\]                  Bladder                                                               3.27                   2.09   2.22                     1.89
  \[[@B7]\]                  Cervical                                                              na                     Na     1.59                     1.14
                             Endometrial                                                           na                     Na     0.74                     0.88
  \[[@B7]\]                  Esophageal                                                            6.76                   4.46   7.75                     2.79
  \[[@B7]\]                  Larengeal                                                             14.60                  6.34   13.02                    5.16
  \[[@B7]\]                  Leukemia                                                              1.86                   1.33   1.13                     1.38
  \[[@B13]\]                 Lung                                                                  22.25                  6.06   21.15                    5.75
  \[[@B7]\]                  Lip, bucal, pharynx                                                   10.89                  3.40   5.08                     2.29
  \[[@B7]\]                  Pancreatic                                                            2.31                   1.15   2.25                     1.55
  \[[@B7]\]                  Renal                                                                 2.72                   1.73   1.29                     1.05
  \[[@B7]\]                  Stomach                                                               1.96                   1.47   1.36                     1.32
  \[[@B13],[@B30]\]          Unspecified                                                           2.31                   1.41   1.83                     1.26
  \[[@B13],[@B30]\]          Other cancers (a)                                                     4.16                   1.83   1.06                     1.01
                             **Respiratory:**                                                                                                              
  \[[@B13]\]                 Tuberculosis                                                          3.49                   1.92   2.51                     2.32
  \[[@B13]\]                 Bronchitis                                                            19.66                  5.67   19.67                    7.55
  \[[@B13]\]                 COPD inc emphysema                                                    21.08                  5.97   19.09                    8.05
  \[[@B13]\]                 Pneumonia                                                             3.99                   1.96   2.21                     1.68
  \[[@B13],[@B31]\]          Asthma adults                                                         1.99                   1.26   2.18                     1.48
  \[[@B13],[@B30],[@B32]\]   Other respiratory (b)                                                 1.94                   1.25   3.09                     2.17
                             **Vascular:**                                                                                                                 
  \[[@B13]\]                 Rheumatic heart disease                                               2.17                   1.17   2.01                     1.18
  \[[@B7]\]                  Aortic aneurism                                                       6.21                   3.07   7.07                     2.07
  \[[@B13]\]                 Coronary artery disease                                               2.87                   1.55   3.03                     1.49
  \[[@B13]\]                 Coronary heart disease                                                2.71                   1.51   3.01                     1.49
  \[[@B13],[@B30]\]          Cardiac dysrhythmias                                                  4.29                   1.93   4.29                     1.66
  \[[@B13],[@B30]\]          Myocardial infarction                                                 2.01                   1.31   8.84                     3.44
  \[[@B13],[@B30]\]          Peripheral vascular disease                                           7.73                   3.03   7.73                     3.09
  \[[@B7],[@B13],[@B30]\]    Other heart diseases (c)                                              2.17                   1.25   2.02                     1.19
                             Cerebrovascular disease                                                                                                       
  \[[@B13]\]                 Ages 35-64                                                            2.47                   1.35   2.15                     1.35
  \[[@B13]\]                 Ages 65+                                                              1.74                   1.16   1.85                     1.26
                             **Digestive system:**                                                                                                         
  \[[@B17]-[@B21]\]          Crohn's disease                                                       1.70                   1.22   1.70                     1.22
  \[[@B14]-[@B16]\]          Peptic ulcers                                                         2.00                   1.28   2.36                     1.39
  \[[@B17]-[@B23]\]          Ulcerative colitis                                                    0.70                   1.55   0.70                     1.55
                             Endocrine-metabolic                                                                                                           
  \[[@B13]\]                 Diabetes                                                              1.86                   1.31   1.62                     1.31
                             **Other:**                                                                                                                    
                             Parkinson's disease                                                   0.37                   0.76   0.36                     0.69
                             \(a\) includes breast, respiratory in situ, renal pelvis and vulvar                                                          
                             \(b\) includes cough, dsypnoea and other respiratory diseases                                                                

Calculation of SAM due to active smoking
----------------------------------------

We assumed persons who died younger had shorter lag-times (between the act of smoking and SAM) than persons who died at an older age \[[@B6]\]. Estimates of the lag-time where made by subtracting the disease and gender-specific average age at death by the gender-specific average age of smokers.

We assumed a lag time for all diagnoses of 2.5, 5, 7.5 and 10 years for persons aged 20--24, 25--29, 30--34 and for, 35--39-year-olds, reflecting the fact that the lengthy lag-times for active smoking (e.g. 25--40 years) are non-feasible in young persons.

A disease-specific age-related linear factor was applied to the 40--54-year age group (i.e. with lower than average time-lag). The average disease-specific lag-time was assumed to occur in the 55--59-year-age group. The average lag time estimates that we used varied from 23.7 years from brain cancer to 40.4 years for coronary artery disease.

A disease specific age-related linear factor was also applied to the over 60 age group (i.e. with increasing above average lag-time) within the constraints of achieving the overall average disease and gender-specific time lag. Next, for each diagnostic, age and gender group, smoking prevalence was obtained for the year relating to 2014 less the lag-time.

Data on RR was combined with lagged smoking prevalence data based on the following formula applied to each diagnosis, age and gender category and finally aggregated \[[@B7]\]:

SAM = Number who died in each category x Smoking Attributable Fraction (SAF)

where

$$\begin{array}{ll}
{{SAF}\  =} & \left. \left\lbrack {\left( {p0\  + \ p1\left( {{RR}1} \right)\  + \ p2\left( {{RR}2} \right)} \right)\  - \ 1} \right\rbrack/ \right. \\
 & \left\lbrack {p0\  + \ p1\left( {{RR}1} \right)\  + \ p2\left( {{RR}2} \right)} \right\rbrack \\
\end{array}$$

and

P0 = Percentage of never smokers

P1 = Percentage of current smokers

P2 = Percentage of former smokers

RR1 = Relative risk of death for current smokers relative to never smokers

RR2 = Relative risk of death for former smokers relative to never smokers

Calculation of SAM due to passive smoking and residential fires
---------------------------------------------------------------

Deaths caused by passive smoking in Israel were estimated by adjusting the US figure \[[@B13]\] of 9.44% of active SAM by the relative differences in smoking prevalence between the USA (males 16.7%, females 13.6%) \[[@B13],[@B33]\] and Israel (males 24.9%, females 12.6%) in 2010 \[[@B4],[@B34]\].

In order to estimate foetal SAM in Israel, USA data showing foetal SAM to be 0.232% of active SAM \[[@B13]\] was adjusted

a\) By the ratio of the Israeli National Smoking prevalence in pregnant women of 6.82%, (as a result of 46.5% of pregnant women stopping smoking) \[[@B34]\] to the USA figure of 8.43% \[[@B35]\].

b\) By Israel's 30.6% higher birth rate \[[@B36],[@B37]\] to give an estimate that foetal SAM accounts for 0.244% of active SAM in Israel.

Deaths caused by residential fires related to cigarette causes was estimated by adjusting the US figure \[[@B13]\] of 0.14% of active SAM deaths by the relative differences by the smoking prevalence between the USA and Israel

Cost of treating smoking-attributable morbidity
-----------------------------------------------

The initial morbidity cost estimates includes only of the direct costs of acute care viewed from a "narrow" health services perspective as there are no readily available data in Israel on costs that fall outside the health system, such as work absences, transportation to receive treatment and out-of-pocket expenses.

Active Smoking Attributable hospitalization days (SAHD) were calculated in a similar way to acute SAM estimates. These were based on actual numbers of diagnosis specific hospitalization utilization rates by age and gender from 2011, being applied to population data in 2014.

Hospitalization costs were calculated by summing:-

a\) The product of the estimated number of hospitalization days in non-ICU units by the 2,251 New Israeli Shekels (NIS) per day tariff of the Ministry of Health \[[@B38]\]

and

b\) Based on ICU accounting for 4.6% of adult non-obstetric general bed use \[[@B39]\], the product of ICU hospitalization days and 5,046 NIS, being 224% times the per-diem cost of non-ICU hospitalizations \[[@B39]\].

An approximation of the other non-acute direct costs (such as for medications, ambulatory care, nursing home care and rehabilitation) attributable to smoking was based on applying the latest estimate from the USA \[[@B13]\] showing that non-acute direct costs were 97.8% of smoking attributable acute care costs.

A further very rough approximation of "indirect costs" in Israel was based on USA data \[[@B13]\] showing that lost productivity costs alone, due to current and ex-smokers having higher rates of absenteeism than never smokers, to be 225% that of the costs of smoking attributable acute hospital care \[[@B13]\]. This impact was "dose related" in the sense that heavy smokers having higher levels of absenteeism than lighter smokers \[[@B40]\].

Results
=======

The updated lagged model estimated active SAM in Israel in 2014 to be 7,025 deaths (95% CI 6,875-7,175), after taking into account an estimated 174 and four fewer deaths, due to the protective effects of smoking on Parkinson's disease and endometrial cancers respectively (Table [2](#T2){ref-type="table"}). Cardio-vascular causes accounted for 45.0% of SAM, malignant neoplasms (39.2%) and respiratory diseases (15.5%). Six specific diagnoses alone accounted for over three-quarters of SAM:- Lung Cancer (24.1%), Coronary Artery Disease (18.5%), COPD including emphysema (13.0%), Myocardial Infarction (10.9%), Cerebrovascular Disease (6.1%) and Coronary Heart Disease (5.0%). Around 60.6% of SAM occurred in males.

###### 

Active smoking attributable mortality-Israel 2014

                                  **Males**   **Females**   **Total**
  ----------------------------- ----------- ------------- -----------
  **Cancers:**                                                       
  Bladder                               155            27         182
  Cervical                                0            10          10
  Endometrial                             0            -4          -4
  Esophageal                             65             2          67
  Larengeal                              54             7          61
  Leukemia                               90            13         103
  Lung                                 1127           562        1690
  Lip, bucal, pharynx                    29            11          39
  Pancreatic                            169           108         276
  Renal                                  70             7          77
  Stomach                               109            23         132
  Unspecified                            43            23          67
  Ureter                                  2             0           2
  Other cancers                          39             9          48
  **Respiratory:**                                                   
  Tuberculosis                            3             0           3
  Bronchitis                              6             4           9
  COPD inc emphysema                    522           394         916
  Pneumonia                              10             2          13
  Asthma adults                          10            22          32
  Other respiratory                      55            58         114
  **Cardio-vascular:**                                               
  Rheumatic heart disease                12            14          27
  Aortic aneurism                        60            30          90
  Coronary artery disease               808           489        1297
  Coronary heart disease                190           164         355
  Cardiac dysrhythmias                   36            23          59
  Myocardial infarction                 266           499         765
  Peripheral vascular disease            54            77         132
  Other heart disease                     4             1           5
  Cerebrovascular disease               230           200         430
  **Digestive system:**                                              
  Crohn's disease                         1             1           2
  Peptic ulcers                           2             3           5
  Ulcerative colitis                   -0.1          -0.1        -0.2
  **Endocrine-metabolic:**                                           
  Diabetes                              115            80         194
  **Other:**                                                         
  Parkinson's disease                   -80           -94        -174
  Total                                4256          2769        7025

Passive (or enforced smoking was estimated to account for an additional 11.29% of active SAM in Israel, amounting to estimated 793 further deaths. Exposure of the foetus to mothers smoking accounted for an estimated 0.24% of active SAM, or 17 additional foetal deaths. While residential fire accounted for an estimated 0.17% of active SAM, or 12 additional deaths. Therefore total SAM will be around 7,847 deaths (95% CI 7,698-7,997) in 2014 or 16.8% of overall expected mortality.

The model estimated that there were 319,231 (95% CI 313,135-325,326) active SAHD days in Israel in 2014 (Table [3](#T3){ref-type="table"}). Respiratory care accounted for around one-half of active SAHD (50.5%). Cardio-Vascular causes accounted for 33.5% and malignant neoplasms (13.2%). Lung cancer accounted for only 4.6%. Around 63.0% of SAM occurred in males.

###### 

Active smoking attributable hospital days-Israel 2014

                                  **Males**   **Females**   **Total**
  ----------------------------- ----------- ------------- -----------
  **Cancers:**                                                       
  Bladder                             7,419           883       8,303
  Cervical                               \-           299         299
  Endometrial                            \-          -308        -308
  Esophageal                            984           478       1,462
  Laryngeal                           1,519           298       1,817
  Leukemia                            2,154           300       2,454
  Lung                                9,392         5,156      14,548
  Lip, bucal, pharynx                 2,252         1,465       3,717
  Pancreatic                          1,530         1,059       2,589
  Renal                               2,206           166       2,372
  Stomach                             1,781           362       2,143
  Unspecified                         1,085           981       2,067
  Other cancers                         395           136         531
  **Respiratory:**                                                   
  Tuberculosis                          281            37         318
  Bronchitis                          4,499         7,520      12,019
  COPD incl. emphysema               29,141        17,857      46,997
  Pneumonia                          44,697        16,441      61,137
  Asthma adults                         616         1,511       2,126
  Other respiratory                  20,618        17,904      38,523
  **Cardio-vascular:**                                               
  Rheumatic heart disease               522           664       1,186
  Aortic aneurisms                    3,071           553       3,624
  Coronary artery disease             3,081         1,009       4,090
  Coronary heart disease              3,064         1,084       4,148
  Cardiac dysrhythmias                  149            99         248
  Myocardial infarction              12,306        13,369      25,676
  Peripheral vascular disease        16,065        13,285      29,350
  Other heart disease                 3,975           908       4,883
  Cerebrovascular disease            21,661        12,079      33,740
  **Digestive system:**                                              
  Crohn's disease                       700           384       1,084
  Peptic ulcers                         114            87         200
  Ulcerative colitis                    -16           -13         -29
  **Endocrine-metabolic:**                                           
  Diabetes                            7,272         3,103      10,375
  **Other:**                                                         
  Parkinson's disease                -1,586          -931      -2,517
  Total hospital days               200,948       118,225     319,173

There were an estimated 36,049 additional SAHD from passive smoking. A further 780 days were attributable to exposure of the foetus to mothers smoking and 541 due to residential fires caused by cigarettes. Therefore total SAHD will be around 356,601 (95% CI 357,908-371,915) days in 2014.

Estimated direct acute care costs of 356,601 days in a general hospital amount to around 849 (95% CI 832--865) million NIS (\$244 million). An additional 830 million NIS (\$238 million) is estimated for out-of hospital costs including ambulatory care, emergency room visits, out- patient visits and rehabilitation. The total health service costs are therefore 1,679 (95% CI 1,646-1,710) million NIS (\$482 million) representing 2.6% of the health budget or 0.2% of GNP. Productivity losses account for a further 1,909 million NIS (\$548 million, based on 225% that of acute care costs of 849 million NIS) giving an overall smoking related cost of 3,587 (95% CI 3,519-3,656) million NIS (\$1,030 million) or 0.41% of GNP.

Discussion
==========

Smoking remains a huge preventable risk factor accounting for approx. 7,847 deaths in Israel (of which 7,025 are from active smoking alone). Approximately one death in every six is attributable to smoking. The monetary impact on health service resources and society amounts to around 3,587 million (\$1,030 million), around 0.41% of GNP.

While Hypertension was originally included in the SAMMEC list \[[@B41],[@B42]\], it has subsequently been dropped and also does not appear in the Surgeon-Generals list. However a recent longitudinal study of 5,512 Japanese males \[[@B43]\] found smoking to be an independent risk factor for hypertension with an adjusted RR of 1.13 (95% CI 1.03 -- 1.23). Applying this risk factor to both genders would add an additional 55 deaths to our acute SAM (and additional 487 acute SAHD).

The decrease of active SAM from previous estimates is partly a result of the secular downward trend in smoking prevalence that has been continuing for the past 40 years, falling in males from 50.6% in 1974 to 36.2% in 1994 and 25.2% in 2013, and from 25.1% to 20.35 and 12.7% among females over the same period.

Another factor is decreases in the size of the RR of diseases such as diabetes, heart and cerebrovascular disease as reported by the US surgeon-general \[[@B13]\]. These however are partially offset by the reported increases in RR of lung cancers \[[@B13]\]. While accounting for nearly a quarter of all acute SAM, lung cancer only accounted for 4.4% of acute SAHD, since chemotherapy and radiotherapy are usually carried out on an out-patient basis, with cancer patients being hospitalized for surgery and hospice care.

The main limitation of the study is that we have made the implicit assumption that the RR which we used were based on data from studies carried out outside of Israel would also apply to the Israeli population. Of course there might be genetic or environmental factors that would result in different disease specific RR based on an Israeli population.

Secondly, the estimation of deaths and costs from passive, mothers smoking and residential fires is by necessity based on US data. Each one of these categories deserves separate calculations to be made based on Israeli specific data. However, due to time limitations, we think it is better to provide a guesstimate based on foreign data, than no estimate at all.

The reader should therefore regard the quality of estimates for active smoking as being good, but the estimates for from passive, mothers smoking and residential fires as being rough first-order estimates.

A recent national Israeli biomarker survey, indicated widespread exposure to environmental tobacco smoke (ETS) in the non-smoking Israeli adult population, especially among males, younger and less educated participants \[[@B44]\]. However the data on urine cotinine concentrations, based on a sample of only 248 persons, did not lend itself to enable estimations of mortality losses due to ETS in Israel. In addition, because good data on past ETS exposure are not currently available in Israel, we only were able to make a rough estimate of the harm due to second-hand smoke exposure based on adapting US data \[[@B13]\].

The resultant rough estimate of 787 deaths due to passive smoking could be an under-estimate or over-estimate as the potential relative exposure levels to passive smoking were just based on one year's smoking prevalence data, instead of over a longer time period.

Also underestimated is the 12 deaths attributable to residential fires (0.175% of active SAM) caused by cigarettes since they do not include an estimate for non-residential fires.

The estimate of non-hospital related direct costs can be thought of as being conservative as it was based on being 97.8% of acute hospital costs \[[@B13]\]. This figure is lower than previously published estimates of 102.1% in Hong-Kong \[[@B45]\]. 102.5% in the USA \[[@B46]\], 107.5% in Germany \[[@B47]\], 113.2% in California \[[@B48]\] 135% in Taiwan \[[@B49]\], 161% in China in 2000 \[[@B50]\] and 273% in China in 2008 \[[@B51]\].

It should be noted that there are health impacts of smoking that do not have mortality consequences. The cost of these are implicitly included in our calculations, where we add 97.8% on to acute hospital costs for non-acute hospital care (such as for infertility on an outpatient basis).

For indirect costs, our estimate can again be thought of as conservative as it only contained estimates of smoking attributable lost productivity costs, thereby excluding transport costs, out-of-pocket expenditures and premature burial costs.

Smoking kills more Israelis than the combined mortality from obesity \[[@B52]\], lack of physical exercise \[[@B53]\], motor vehicle emissions \[[@B54]\], vehicle accidents, suicides and murders \[[@B36]\].

No one single intervention can totally reduce the considerable burden of disease from smoking. A multi-faceted approach is required, combining legislation, counter-advertising, taxation, prevention and cessation interventions \[[@B55]\].

Fortunately, many potential interventions to reduce the human and monetary burden from smoking have been identified and prioritized according to their cost-utility ratios in Israel. Many very cost-effective interventions have been identified in addition to interventions that are cost-saving (ie: where savings in treatment costs exceed the intervention costs). These include imposition of a higher tax on tobacco, Clonidine, Nortiptyline, varenicline (2 mg/day), Quitline Counseling and a combination of Medication and Quitline Counseling. Many interventions were found to be very cost-effective (having a cost per quality adjusted life year (QALY) less than GNP per capita):- Nicotine lozenges, Varenicline (1 mg/day), Nicotine patches with and without Nortipyline or Burropion, Buropropin, Nicotine Gum, Group counseling, Nicotine nasal spray, Individual Counseling, Nicotine inhaler \[[@B5]\]. Other potential interventions, not yet evaluated using cost-effectiveness analysis in Israel include novel cheap modes such as mobile phone text-messaging as well as pack warnings, \'plain' packaging and smoke-free space regulations.

Unfortunately, Israel lags behind many developed nations in that it does not use cost-utility analyses to prioritize the adoption of new health technologies. There may be several reasons for this inadequacy. One reason may be insufficient appreciation within the Ministry of Health of the importance of cost-utility analysis and of recent advances in health economics which facilitate the integration of epidemiological and economic data. Another reason may be that Israel tends to be an early adopter of new technologies, with many new technologies being considered for inclusion in the benefits package well before all the data needed for cost utility analyses are available. However, early adoption of suitable technologies can be still further catalyzed if a-priori cost-utility analyses are carried out during the period between the conclusion of clinical trials and when manufacturers begin marketing the new technology.

Yet another reason for not using cost utility analyses may be a desire to ensure that the members of the benefits package committee (i.e. the committee that determines new entries into the basket of services) will have enough degrees of freedom to take into account considerations that are not captured in cost-utility analyses, such as uniquely Israeli values^a^. However, there is no contradiction between preserving some degrees of freedom for policymakers and providing them with sophisticated cost-utility analyses as key inputs into the decision-making process.

Accordingly, it behooves Israel to find ways to better incorporate cost-utility analyses into its prioritization processes, both with regarding to smoking interventions, and more generally. This could be done either by expanding the role of health economics within the Ministry of Health, or by establishing an institution akin to NICE, or by relying more heavily on non-governmental experts and research institutions.

We would also note that, in areas other than health care, Israel has established funded bodies like the "authority for the war against road accidents" and the "authority for the war against drugs". The considerable mortality burden (around twenty times higher than that caused by traffic related mortality) attributable to smoking in this paper cries out for the establishment of a "national authority" to co-ordinate to identify and implement a multi-faceted intervention strategy to decrease the considerable burden from smoking in Israel.

Conclusion
==========

Smoking causes a considerable burden in Israel, both in terms of the expected 7,847 lives lost and the financial costs of around 3,587 million NIS (\$1,030 million or 0.41% of GNP). Many cost-effective and cost-saving interventions exist that can reduce this huge burden on society.

Endnote
=======

^a^One such uniquely-Israeli value is the high priority given to fertility treatments. At the same time it should be kept in mind that in the case of most major illnesses -- such as lung cancer, myocardial infarction, osteoporosis, stroke or diabetes -- we are unaware of any uniquely Israeli values to be considered.
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